Drugs & Aging

, Volume 24, Issue 2, pp 169–171 | Cite as

Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer

Adis Spotlight

Abstract

Bicalutamide (Casodex®) is a competitive androgen receptor antagonist that inactivates androgen-regulated prostate cell growth and function, leading to cell apoptosis and inhibition of prostate cancer growth. It is administered orally as a once-daily dose. In the EU and a number of other countries, bicalutamide 150 mg/day is approved in men with locally advanced nonmetastatic prostate cancer as immediate therapy either as an adjuvant to active treatment or as monotherapy as an alternative to surgical or medical castration.

Combined analysis of the three trials that comprise the bicalutamide Early Prostate Cancer programme showed that bicalutamide administered in conjunction with standard care in men with locally advanced prostate cancer offers disease-free survival benefits over standard care alone and is generally well tolerated. Overall survival was improved to a greater extent in the subgroup of patients who received bicalutamide plus radiation therapy compared with radiation therapy alone. Men with localised prostate cancer do not benefit from the addition of bicalutamide to standard care. Combined analysis of two other studies in men with locally advanced prostate cancer show that bicalutamide monotherapy offers better tolerability and higher health-related quality-of-life scores for sexual interest and physical capacity compared with surgical or medical castration, while achieving disease-free and overall survival durations that were not significantly different. Thus, when treatment options are being evaluated, bicalutamide as adjuvant therapy or monotherapy should be considered as an alternative to other available hormonal therapies in men with locally advanced prostate cancer, especially in those who wish to maintain an active lifestyle.

Keywords

Prostate Cancer Localise Prostate Cancer Advanced Prostate Cancer Bicalutamide Early Prostate Cancer 

Notes

Acknowledgements

The full text article in Drugs 2006; 66 (6): 837–850 was reviewed by: P.-A. Abrahamsson, Department of Urology, Malmö University Hospital, Lund University, Malmö, Sweden; G. Di Lorenzo, Department of Endocrinology and Oncology and Medical Oncology-Prostate Cancer Center, University of Naples, Naples, Italy; A.V. Kaisary, Royal Free Hospital, London, UK; W. Oh, Lank Center for Genitourinary Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; P.F. Schellhammer, Department of Urology, East Virginia Medical School, Norfolk, Virginia, USA; P. Sieber, Urological Associates of Lancaster, Lancaster, Pennsylvania, USA.

References

  1. 1.
    Klotz L, Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer 2005 Mar; 3(4): 215–9PubMedCrossRefGoogle Scholar
  2. 2.
    Masiello D, Cheng S, Bubley GJ, et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002 Jul 19; 277(29): 26321–6PubMedCrossRefGoogle Scholar
  3. 3.
    Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93(9): 1177–82PubMedCrossRefGoogle Scholar
  4. 4.
    Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994 Oct; 41: 525–30CrossRefGoogle Scholar
  5. 5.
    Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Urology 1996 Jan; 47Suppl. 1A: 26–8PubMedCrossRefGoogle Scholar
  6. 6.
    Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005 Feb 1; 23(4): 808–15PubMedCrossRefGoogle Scholar
  7. 7.
    McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97(2): 247–54PubMedCrossRefGoogle Scholar
  8. 8.
    Iversen P, Tyrrell CJ, Kaisary AM, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000 Nov; 164: 1579–82PubMedCrossRefGoogle Scholar
  9. 9.
    Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004 Jun; 171 (6 Pt 1): 2272–6PubMedCrossRefGoogle Scholar
  10. 10.
    Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004 Jul 1; 22(13): 2546–53PubMedCrossRefGoogle Scholar
  11. 11.
    Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004; 43(13): 855–78PubMedCrossRefGoogle Scholar
  12. 12.
    See WA, McLeod D, Iversen P, et al. The bicalutamide Early Prostate Cancer Program: demography. Urol Oncol 2001; 6: 43–7PubMedCrossRefGoogle Scholar
  13. 13.
    See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002 Aug; 168: 429–35PubMedCrossRefGoogle Scholar
  14. 14.
    Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. J Urol 2004; 172 (5 Pt 1): 1865–70PubMedCrossRefGoogle Scholar
  15. 15.
    Iversen P, Johansson J-E, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 Nov; 172 (5 Pt 1): 1871–6PubMedCrossRefGoogle Scholar
  16. 16.
    Iversen P, Johansson JE, Lodding P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006; 40(6): 441–52PubMedCrossRefGoogle Scholar
  17. 17.
    Wirth M, Tyrrell C, Delaere K, et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis 2006 Nov 14, Epub ahead of printGoogle Scholar
  18. 18.
    McLeod DG, See WA, Klimberg I, et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at7.7-year median followup. J Urol 2006 Jul; 176(1): 75–80PubMedCrossRefGoogle Scholar
  19. 19.
    Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51: 389–96PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Wolters Kluwer Health | AdisMairangi Bay, AucklandNew Zealand
  2. 2.editorial office of Wolters Kluwer HealthConshohockenUSA

Personalised recommendations